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CORRECTIONS
Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CMJ, Lainchbury JG, Nicholls MG, Richards AM,
Vale WW. Beneficial Hemodynamic, Endocrine, and Renal Effects of Urocortin in Experimental Heart Failure: Comparison With
Normal Sheep. J Am Coll Cardiol 2002;40:1495–505. Per the authors, the doses of urocortin were printed incorrectly in the Methods
section of the Abstract (page 1495), the Study Protocol section under the Methods heading (page 1496), and the column headings of
Tables 1 and 2 (pages 1502 and 1503). The correct doses are 10, 50, and 100 g.
doi:10.1016/S0735-1097(03)00886-6
Taylor MRG, Fain PR, Sinagra G, Robinson ML, Robertson AD, Carniel E, Di Lenarda A, Bohlmeyer TJ, Ferguson DA, Brodsky
GL, Boucek MM, Lascor J, Moss AC, Li W-LP, Stetler GL, Muntoni F, Bristow MR, Mestroni L, Familiar Dilated
Cardiomyopathy Registry Research Group. Natural History of Dilated Cardiomyopathy Due to Lamin A/C Gene Mutations. J Am
Coll Cardiol 2003;41:771– 80. The authors have detected some inconsistencies and inaccuracies within the aforementioned paper. Please
see below for list of corrections:
TEXT
The informed consent statement (page 772, 2nd column, 1st paragraph) should have read:
Deoxyribonucleic acid samples from subjects and controls were obtained according to the contemporaneous consent guidelines in place in
Italy and the U.S.
In the Abstract (page 771), Methods (page 772), and Tables 1 (page 772) and 3 (page 777), 105 subjects (104 with DCM and 1 with
asymptomatic carrier) were included in the statistical analysis.
FIGURES
Figure 1 (page 773): The light gray circles indicate individuals with “unknown” status as defined in the Methods section.
Figure 2 (page 774): The word nucleotide should have been amino acid.
Figure 3 (page 776): The light gray boxes indicate divergent amino acids.
TABLES
Table 2 (page 774–5): In the Mutation column, the third mutation G1130T should have been G1130A. In the ID column for Family
TSFDC13, the ID numbers should read, from top to bottom, II-1, III-2, III-1. For Family MDDC1, individual II-5 should have been II-3.
For this family, the screening of controls utilized normal controls and samples from explanted DCM hearts. There was an insertion of an extra
space in the Conduction column, both individuals II-1 and II-3 had 2°–3° AV block and left bundle-branch block. The intent of this Table is
to provide a description of the phenotypes of the 12 carriers; it reflects the most up-do-date information collected on these subjects.
Table 3 (page 777): The Age of onset values should have been 37 for non-carriers and 27 for carriers. Skeletal muscle involvement should have
been Muscular disease. Conduction defects should have been 11% for non-carriers and 50% for carriers. All of the percentages in this Table
cannot be derived from Table 2. This Table represents a comparison of data collected at enrollment between the carriers and non-carriers.
The authors apologize for the inconvenience generated by these corrections.
None of these errors/changes alters the results or conclusions of the manuscript.
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